5
Participants
Start Date
November 2, 2017
Primary Completion Date
June 17, 2022
Study Completion Date
June 17, 2022
F-FDG PET/CT
F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
University of Wisconsin Carbone Cancer Center, Madison
National Cancer Institute (NCI)
NIH
University of Wisconsin, Madison
OTHER